Smartweave, Inc.

Personalized connective tissue treatments. For patients who deserve better than one-size-fits-all.

https://wefunder.com/smartweave.inc

Total raised on Wefunder: 204006

Total investors: 46

Quick facts

  • One of fifteen startups that were selected by Swiss EPFL affiliated Tech4Eva from 300+ ventures
  • $6.4M in grants and institutional support secured before opening raise
  • Key collaborators secured $12M+ to move enabling R&D toward pre-IND stage.
  • Lab-validated technology shown to reduce inflammation, repair tendons, and restore continence.
  • 150+ years of combined expertise from top institutions in therapeutics, devices, and R&D.
  • Generated $3.5M from IP in 2 years, with product and licensing revenue growing.
  • Multiple US patents secured, growing to 50+ across AI, scaffolds, and 3D printing.
  • $100B+ connective tissue restoration market projected by 2030.

Team profiles

Featured investor profiles

Invest in Smartweave, Inc.

Personalized connective tissue treatments. For patients who deserve better than one-size-fits-all.

FIRST GOAL HIT (You can still invest)

$246,006

raised from 50 investors
INVESTMENT TERMS
Future Equity
$35M valuation cap
$10K, $25K

What Investors Say

LEAD INVESTOR
Invested $5,000 this round + $25,000 previously
I met Raj at an investors conference in early 2025. As an emerging fund manager and technologist was intrigued by the idea, I was immediately drawn to his vision for truly personalized surgical solutions.
The validation from Dassault Systems, selecting Smartweave as one of just three startups from over 1,000s applicants globally spoke volumes. But more importantly, the concept of using digital twins to design implants tailored to each patient's unique anatomy felt like the future of personalized medicine finally arriving. After years of one-size-fits-all approaches causing preventable complications, here is a platform that could actually optimize surgical outcomes for individuals, not masses.
What ultimately convinced me to invest, though, went far beyond the software. Smartweave has built serious clinical and translational depth, collaborating with prestigious teaching hospitals like Stanford Medicine and Cedars-Sinai on regenerative therapeutics for pelvic floor, dental, cardiac, and tendon repair. Between Smartweave and its clinical partners, the underlying science and platforms have already attracted nearly $20M in competitive, non-dilutive grant funding, which is being used to systematically derisk the tech stack from advanced bioactive gels and tissue-integrating scaffolds all the way through to pre-IND–stage programs. This isn’t a pitch-deck biotech; it’s an integrated ecosystem of digital twins, personalized implants, and regenerative biologics that have been pressure-tested by top academic centers and funding bodies.
In my view, Smartweave is positioned to transform the surgical implant and regenerative therapeutics market by making truly personalized, biology-aware care accessible at scale. The healthcare industry has been stuck in incrementalism for far too long. This is one of the few teams I’ve seen that actually has the technical, clinical, and regulatory pieces in place to deliver on the promise of precision surgery and regenerative medicine. I am not just comfortable being an early investor, also excited to help them bring this to patients.
What People Say